Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Kyung-Eui Park"'
Autor:
Ji-Hye Nam, Min-Soo Kim, Young-Jo Song, Chang-Hwan Kim, Wang Soo Kim, Chi Ho Yu, Hae Eun Joe, Gyeung Haeng Hur, Myeung-Ryun Seo, Yeongmun Kim, Kyung Eui Park, Jun Young Choi, Suk-Jae Chung, Young Kee Shin
Publikováno v:
Archives of Toxicology. 97:697-710
Autor:
Nam Ah Kim, Sungyoul Hong, Ki Hyun Kim, Du Hyung Choi, Joo Seok Kim, Kyung Eui Park, Jun Young Choi, Young Kee Shin, Seong Hoon Jeong
Publikováno v:
Pharmaceutics, Vol 12, Iss 2, p 121 (2020)
c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Unlike other c-Met inhibitors that fail clinically, ABN401 is a newly synthesized c-Met inhibitor that is not potentially
Externí odkaz:
https://doaj.org/article/d47a1325e7ed40efa896452cd874650d
Publikováno v:
Cancer Research. 83:382-382
ABN401, a highly selective c-MET inhibitor, is being evaluated for the treatment of non-small cell lung cancer (NSCLC) in clinical trials. NSCLC is a heterogeneous in nature and leading cause in cancer related mortality. Numerous studies are still on
Autor:
Kyung-eui Park, Joon-Seok Choi, Hye Bin Ahn, Yeong Mun Kim, Sungyoul Hong, Yong Jin Lee, Hun Seok Lee, Seong Tae Jeong, Sung Hyun Hong, Yoon-Kyu Lim, Gyeung Haeng Hur, Jun Young Choi, Young Kee Shin, Won Rak Son, Kyoung Song, Chi Ho Yu, Saehyung Lee, Jong-pil Seo, Jaehyuk Yang, Tae Jin Kang, Na Young Kim
Publikováno v:
Journal of Microbiology and Biotechnology. 29:1165-1176
Botulinum neurotoxins (BoNTs), produced by Clostridium botulinum, are the most toxic substances known. However, the number of currently approved medical countermeasures for these toxins is very limited. Therefore, studies on therapeutic antitoxins ar
Autor:
Jae Jun Shin1,2, Kyung Eui Park1, Young Min Choi1,3 ymchoi@snu.ac.kr, Hye-Ok Kim4, Dong-Hee Choi5, Woo Sik Lee6, Jung-Hyun Cho6
Publikováno v:
Clinical & Experimental Reproductive Medicine. Sep2018, Vol. 45 Issue 3, p135-142. 8p.
Autor:
Dae Ho Lee, Aflah Roohullah, Byoung Chul Cho, Charlotte Rose Lemech, Paul L. de Souza, Michael Millward, Jun Young Choi, Kyung Eui Park, Na Young Kim, EuiYoung Kim, Saehyung Lee, YeongMun Kim, YOUNGKEE Shin, Ji-Youn Han
Publikováno v:
Journal of Clinical Oncology. 40:3105-3105
3105 Background: MET is a proto-oncogene encoding a receptor tyrosine kinase c-MET for hepatocyte growth factor (HGF). Dysregulated MET signaling by MET exon14 skipping, MET gene amplification and c-MET overexpression in cancer plays a critical role
Autor:
Michael Millward, Y. Kim, Young Kee Shin, J. Kim, Mark T Lee, Jongmin Lee, Jun Young Choi, Charlotte Lemech, J-Y. Han, S. Park, Aflah Roohullah, P. de Souza, Dae Ho Lee, Byoung Chul Cho, Kyung Eui Park
Publikováno v:
Annals of Oncology. 32:S1029-S1030
Autor:
Michael Millward, Charlotte Lemech, Ji-Youn Han, Aflah Roohullah, Y. Kim, Paul de Souza, Jun Young Choi, Dae Ho Lee, Minseon Lee, Byoung Chul Cho, Young Kee Shin, Kyung Eui Park
Publikováno v:
Journal of Clinical Oncology. 39:TPS3157-TPS3157
TPS3157 Background: c-MET (hepatocyte growth factor (HGF) receptor) overexpression, either by gene amplification, or mutation is associated with oncogenic transformation in numerous malignancies including lung, gastric, skin, renal, colorectal, and p
Autor:
Yong Jin Kim, Moon Suk Kim, Byeong Cheol Kang, Soohyun Kim, Kyung Cheon Jung, Kyung Mee Cho, Seung Yup Ku, Kyung Eui Park, Yoon Young Kim
Publikováno v:
Tissue Engineering and Regenerative Medicine. 13:724-731
Freezing and thawing is one of the most widely used tissue engineering techniques for the preservation of ovaries. Many cells and tissues demonstrate changes in functional gene expression after thawing. Several studies have reported the important rol
Autor:
Seong Hoon Jeong, Sungyoul Hong, Ki Hyun Kim, Kyung Eui Park, Nam Ah Kim, Joo Seok Kim, Young Kee Shin, Du Hyung Choi, Jun Young Choi
Publikováno v:
Pharmaceutics, Vol 12, Iss 2, p 121 (2020)
Pharmaceutics
Volume 12
Issue 2
Pharmaceutics
Volume 12
Issue 2
c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Unlike other c-Met inhibitors that fail clinically, ABN401 is a newly synthesized c-Met inhibitor that is not potentially